Personalized T cell-mediated cancer immunotherapy: progress and challenges.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer immunotherapies are increasingly effective against various cancers.
• Traditional approaches targeted public tumor antigens, leading to mixed results and adverse events.
• Emerging research highlights the importance of private, tumor-specific neoantigens in anti-tumor immunity.

Purpose of the Study:

• To review progress in personalizing T cell-mediated cancer immunotherapy.
• To discuss the challenges and future directions in neoantigen-targeted therapies.

Main Methods:

• Exome sequencing for neoantigen discovery in highly mutated cancers.
• T cell receptor repertoire sequencing as a potential technology for low-mutational burden cancers.

Main Results:

• Neoantigen identification is advancing, particularly for cancers like melanoma.
• Personalized targeting offers potential for safer and more durable tumor regression.
• Current technologies are effective for highly mutated cancers but need enhancement for others.

Conclusions:

• Targeting neoantigens is central to endogenous anti-tumor immunity.
• Accelerating the process from neoantigen discovery to therapeutic application is a key challenge.
• New technologies are needed to identify neoantigens in cancers with low mutational burden.